Version 1
: Received: 18 September 2019 / Approved: 19 September 2019 / Online: 19 September 2019 (04:59:36 CEST)
How to cite:
Maifata, S.M.; Hod, R.; Zakaria, N.F.; Abd Ghani, F. Membranous Glomerulonephritis: Overview of the Role of Serum and Urine Biomarkers in the Management. Preprints2019, 2019090218. https://doi.org/10.20944/preprints201909.0218.v1
Maifata, S.M.; Hod, R.; Zakaria, N.F.; Abd Ghani, F. Membranous Glomerulonephritis: Overview of the Role of Serum and Urine Biomarkers in the Management. Preprints 2019, 2019090218. https://doi.org/10.20944/preprints201909.0218.v1
Maifata, S.M.; Hod, R.; Zakaria, N.F.; Abd Ghani, F. Membranous Glomerulonephritis: Overview of the Role of Serum and Urine Biomarkers in the Management. Preprints2019, 2019090218. https://doi.org/10.20944/preprints201909.0218.v1
APA Style
Maifata, S.M., Hod, R., Zakaria, N.F., & Abd Ghani, F. (2019). Membranous Glomerulonephritis: Overview of the Role of Serum and Urine Biomarkers in the Management. Preprints. https://doi.org/10.20944/preprints201909.0218.v1
Chicago/Turabian Style
Maifata, S.M., Nor Fadhina Zakaria and Fauzah Abd Ghani. 2019 "Membranous Glomerulonephritis: Overview of the Role of Serum and Urine Biomarkers in the Management" Preprints. https://doi.org/10.20944/preprints201909.0218.v1
Abstract
Detection of PLA2R and THSD7A among primary membranous glomerulonephritis (MGN) patients transformed the diagnosis, treatment monitoring and prognosis. Anti-PLA2R can be detected in 70-90% of primary MGN patients while anti-THSD7A in 2-3% of anti-PLA2R negative primary MGN patients depending on the technique used. Serum and urine samples are less invasive and non-invasive respectively and can detect the presence of anti-PLA2R and anti-THSD7A with higher sensitivity and specificity, significant in patients’ monitoring and prognosis better than exposing patients to frequent biopsy which is an invasive procedure. Different techniques of detection of PLA2R and THSD7A in patients’ urine and sera were reviewed with the aim of providing newer and alternative techniques. We proposed the use of biomarkers (PLA2R and THSD7A) in making the diagnosis, treatment decision and follow up of patients with primary MGN. We also reviewed other prognostic renal biomarkers like retinol binding protein (RBP) and beta-2 microglobulin in order to detect progression of renal damage for early intervention.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
